Evidence map›Paper›PMID 41727781›Full record

ArticleKidney international reports2026

Immune Profiling Identifies High-Risk Neutrophil-Rich Subtype in Checkpoint Inhibitor Nephritis.

Idris Boudhabhay, Helene Lazareth, Julie Oniszczuk, Mathilde Burki, Olivier Aubert, Alaeddine Redissi, Hamza Sakhi, Elsa Ferriere, Elizabeth Fabre, Francesca Lucibello and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Idris BoudhabhayCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Helene LazarethParis Cité University, Paris, France.
Julie OniszczukDepartment of Nephrology, Foch Hospital, Suresnes, Paris, France.
Mathilde BurkiDepartment of Nephrology and Kidney Transplantation, Felix Guyon Hospital, Saint-Denis, La Réunion, France.
Olivier AubertDepartment of Nephrology and Kidney Transplantation, Necker Hospital, Assistance publique - Hôpitaux de Paris (AP-HP), Paris, France.
Alaeddine RedissiCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Hamza SakhiDepartment of Nephrology and Kidney Transplantation, Necker Hospital, Assistance publique - Hôpitaux de Paris (AP-HP), Paris, France.
Elsa FerriereDepartment of Nephrology and Kidney Transplantation, Necker Hospital, Assistance publique - Hôpitaux de Paris (AP-HP), Paris, France.
Elizabeth FabreDepartment of Thoracic Oncology, European Hospital Georges Pompidou, AP-HP, Paris, France.
Francesca LucibelloInstitut Curie, Institut du Thorax, Paris, France.
Nicolas GirardInstitut Curie, Institut du Thorax, Paris, France.
Anne GrunenwaldCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Houcine HamidiCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Emma FleuryCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Marie Agnes Dragon-DureyCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Florence RunyoDepartment of Nephrology, Foch Hospital, Suresnes, Paris, France.
Camille CohenParis Cité University, Paris, France.
Stephanie ChhunLaboratory of Immunology, Hôpital Necker-Enfants Malades, AP-HP, Centre-Université de Paris, Paris, France.
Nicolas VeyrencheDepartment of Clinical Microbiology, Necker-Enfants Malades Hospital, AP-HP Centre Université de Paris Cité, Paris, France.
Anne JametParis Cité University, Paris, France.
Jacques FourgeaudDepartment of Clinical Microbiology, Necker-Enfants Malades Hospital, AP-HP Centre Université de Paris Cité, Paris, France.
Béatrice RegnaultPathogen Discovery Laboratory, Institut Pasteur, Université Paris Cité, Paris, France.
Philippe PérotPathogen Discovery Laboratory, Institut Pasteur, Université Paris Cité, Paris, France.
Marie-Sophie MeulemanCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Celine MayingaCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Alexandre KarrasParis Cité University, Paris, France.
Jean-Paul Duong Van HuyenCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Marion RabantParis Cité University, Paris, France.
Lubka T RoumeninaCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Pierre IsnardParis Cité University, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Immune checkpoint inhibitor (ICI)-induced acute interstitial nephritis (AIN) (ICI-AIN) is the leading cause of ICI-associated acute kidney injury (AKI). ICI-AIN is characterized by mononuclear immune infiltrates, although the mechanisms behind their toxicity remain unclear. We aimed to characterize these infiltrates in kidney biopsies and assess their correlation with clinical outcomes and therapeutic responses. Methods: We retrospectively analyzed 49 biopsy-proven ICI-AIN cases using multiplex immunofluorescence to quantify immune cells (macrophages, neutrophils, B cells, T cells, and plasmocytes). Unsupervised clustering was used to identify patient groups, which we then correlated with clinical presentation and outcomes. Finally, we explored the role of C5a/C5aR1 in neutrophil recruitment. Results: Unsupervised clustering revealed 3 immune phenotypes as follows: (i) low mononuclear (cluster 1), (ii) high mononuclear (cluster 2), and (iii) neutrophil-rich (cluster 3). Cluster 3 was associated with higher systemic inflammation (C-reactive protein: 84 vs. 15-24 mg/l, Conclusion: Our findings identify distinct ICI-AIN subtypes, with a neutrophil-rich cluster linked to complement activation and poor prognosis, offering insights into refining diagnosis and treatment strategies.

Indexed as

acute interstitial nephritischeckpoint inhibitorscomplementimmune phenotypingimmunotherapyneutrophil

Identifiers

PMID41727781
PMCPMC12918167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.